Tempest Therapeutics Commences ~$2.5M Offering Of 3.106M Common Shares At $0.805 Per Share
Tempest Therapeutics, Inc. (Nasdaq: TPST) (the "Company"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced
Tempest is selling new shares of its stock to raise about 2.5 million dollars for its research and operations. When a company does this, it can mean they need cash right now, so watch if the stock price stays steady or if investors seem worried about the extra shares.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.